Great work. The clear objective of making timely progress is reassuring, as is the absence of any adverse reactions (the endpoint of a phase 1 trail).
Ann: Amplia Initiates Multiple Dose Study of AMP945, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
0.015(5.56%) |
Mkt cap ! $110.7M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 28.5¢ | 27.3¢ | $695.3K | 2.492M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 147536 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 52593 | 2 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| ATX (ASX) Chart |